Qurucell CAR-T 'Limcato' Phase 2 Clinical Trial Results Published in Leading Hematology Journal

Published in the International Journal "Blood"

Therapeutic response observed in 75.3% of patients... 67.1% achieved complete remission

Incidence rates: grade 3 or higher cytokine release syndrome at 8.9%, neurotoxicity at 3.8%

On June 15, Qurucell announced that the results of its phase 2 clinical trial for the CAR-T therapy Limcato (ingredient name: AnbalcaptaGene Autoleucel) have been published in the international hematology journal "Blood."

Exterior view of Curocell's Daejeon headquarters (research institute) and GMP factory. Curocell

This paper presents the results of Limcato's phase 2 clinical trial (CRC01). According to the Independent Review Committee (IRC) assessment criteria, the objective response rate (ORR) was 75.3%, and the complete remission rate (CR) was 67.1%. In the safety evaluation, the incidence rate of grade 3 or higher cytokine release syndrome (CRS) was 8.9%, and the incidence rate of neurotoxicity (NE) was 3.8%.

"Blood" is a leading international hematology journal published by the American Society of Hematology (ASH), featuring research results in hematologic cancers such as leukemia, lymphoma, multiple myeloma, as well as in the field of cell and gene therapy.

Qurucell plans to leverage the publication of this paper to release Limcato's clinical data to the global academic community and utilize it to expand business development opportunities, including global partnerships and technology transfer.

Limcato became the first CAR-T therapy to receive product approval from the Ministry of Food and Drug Safety in Korea in April. Qurucell continues to develop next-generation cell and gene therapies based on the research and development, clinical, GMP manufacturing, and quality control capabilities acquired during the development process of Limcato.

This content was produced with the assistance of AI translation services.